{"publisher":{"name":"MediaBias News","url":"https://mediabias.news","methodology":"https://mediabias.news/methodology","editorialPrinciples":"https://mediabias.news/editorial-principles","corrections":"https://mediabias.news/corrections"},"scoreGuide":{"trust":"How well corroborated and evidenced the source reporting is. 0-100, higher is better.","critic":"Craft quality of the source journalism: context, balance, fact vs comment. 0-100, higher is better.","hype":"How far the source presentation runs ahead of substance. 0-100, LOWER IS BETTER.","scope":"Scores assess the original reporting this article was written from, not the truth of the underlying event and not the quality of this write-up."},"assessmentGuide":{"type":"coverage-and-source-reporting-analysis","factCheck":{"status":"not-performed","note":"Media Bias News compares coverage and scores the source reporting. It does not currently publish a ClaimReview verdict on whether the underlying event or claim is true."},"sourceFactuality":{"note":"Factuality values describe published ratings of the outlets that covered the story. They are not a factuality verdict on this story or its claims."}},"story":{"id":"https://mediabias.news/politics/us-treasury-plans-rules-for-china-pharma-deals","slug":"us-treasury-plans-rules-for-china-pharma-deals","url":"https://mediabias.news/politics/us-treasury-plans-rules-for-china-pharma-deals","title":"US Treasury plans rules for China pharma deals","subtitle":"New regulations would likely permit most licensing agreements, with exceptions for sensitive biotechnology.","excerpt":"The U.S. Treasury Department is developing rules for biopharmaceutical companies investing in China. These regulations are expected to allow most licensing deals for drugs originating in China, with potential restrictions on weaponizable biotechnology or pathogens. The move aims to balance economic interests with national security concerns.","category":"Politics","area":"United States","publishedAt":"2026-09-18T21:05:12.307Z","sourceReportedAt":"2026-09-18T18:40:01.000Z","updatedAt":"2026-09-18T21:05:12.307Z","readTime":"2 min read","scores":{"trust":50,"critic":45,"hype":20,"notes":{"trust":"Central claim attributed to named body (Reuters) and three sources, but no documents or independent outlets.","critic":"Reporting is clear and holds together, but lacks quotes from affected parties or discussion of future implications.","hype":"The language used is measured and proportionate, with no sensationalism or manufactured urgency."}},"tags":["#USChinaRelations","#Biotechnology","#Pharmaceuticals","#TreasuryDepartment","#InternationalTrade"],"entities":["U.S. Treasury Department","China","Pfizer","Reuters"],"body":[{"type":"key_takeaways","items":["The U.S. Treasury Department is formulating rules for biopharma companies investing in China.","The proposed rules would likely permit most licensing deals for drugs originating in China.","Exceptions may apply to deals involving weaponizable biotechnology or pathogens.","Some U.S. pharmaceutical leaders favour fewer restrictions, while others urge caution."]},{"type":"paragraph","text":"The U.S. Treasury Department is formulating rules that would govern biopharmaceutical companies investing in China. These regulations are expected to allow the majority of licensing deals for drugs that originate in China. The rules may include exceptions for deals involving weaponizable biotechnology or pathogens, according to three sources familiar with the matter who spoke to Reuters."},{"type":"heading","text":"Divergent views on China investment"},{"type":"paragraph","text":"Within the U.S. pharmaceutical industry, there are differing opinions on the extent of restrictions that should be placed on investments and collaborations with China. Leaders such as the CEO of Pfizer have expressed opposition to broad restrictions, stating they foresee no security threat in most collaborations. Conversely, some executives from smaller biotechnology firms have voiced concerns about strategic reliance on China and are advocating for increased caution."},{"type":"heading","text":"What the coverage left out"},{"type":"paragraph","text":"None of the centre- or right-rated reports mention the specific reasons why U.S. and European drugmakers are increasingly collaborating with Chinese biopharma companies, such as seeking access to innovative medicines to replenish pipelines ahead of patent expirations on major drugs, as reported by Reuters in its full report."}],"basedOn":[{"sourceName":"Cryptocurrency News | Cryptocurrency Prices | Market Cap","url":"https://cryptocurrency.com.tr/us-treasury-department-drafts-rules-to-keep-most-pharma-licensing-deals-with-china-alive-382726","headline":"US Treasury Department drafts rules to keep most pharma licensing deals with China alive","angle":"","publishedAt":"2026-09-18T18:40:01.000Z"},{"sourceName":"Crypto Briefing","url":"https://cryptobriefing.com/us-treasury-pharma-licensing-rules-china","headline":"US Treasury Department drafts rules to keep most pharma licensing deals with China alive","angle":"","publishedAt":"2026-09-18T18:40:01.000Z"},{"sourceName":"OODA Loop","url":"https://oodaloop.com/briefs/technology/us-weighs-allowing-most-pharma-licensing-deals-with-china","headline":"US weighs allowing most pharma licensing deals with China","angle":"","publishedAt":"2026-09-18T16:11:32.000Z"},{"sourceName":"Formiche.net","url":"https://formiche.net/2026/09/farmaceutica-usa-cina-licensing-biotech","headline":"Chinese Biotech, Towards New Rules for US Companies? Indiscretions","angle":"","publishedAt":"2026-09-18T13:51:12.000Z"},{"sourceName":"STAT","url":"https://statnews.com/pharmalot/2026/09/18/rules-for-china-licensing-deals-making-drugs-in-space","headline":"Pharmalittle: We're reading about licensing deals with China, making drugs in space, and more","angle":"","publishedAt":"2026-09-18T13:29:38.000Z"},{"sourceName":"iatronet.gr","url":"https://iatronet.gr/article/142917/hpa-exetazetai-epektash-symfonion-adeiodothshs-farmakeytikon-proionton-apo-thn-kina","headline":"US: Expanding Pharmaceutical Licensing Agreements with China Under Consideration","angle":"","publishedAt":"2026-09-18T13:04:45.427Z"},{"sourceName":"regionalmedianews.com","url":"https://regionalmedianews.com/news/national/health/exclusive-us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say","headline":"Exclusive-US weighs allowing most pharma licensing deals with China, sources say - Regional Media News","angle":"","publishedAt":"2026-09-18T12:11:41.000Z"},{"sourceName":"Globo","url":"https://valor.globo.com/empresas/noticia/2026/09/18/eua-avaliam-permitir-maioria-dos-acordos-de-licenciamento-farmacutico-com-a-china-dizem-fontes.ghtml","headline":"U.S. Estimates Allow Most Pharmaceutical Licensing Agreements with China, Sources Say","angle":"","publishedAt":"2026-09-18T12:07:45.000Z"},{"sourceName":"Seeking Alpha","url":"https://seekingalpha.com/news/4644250-usweighs-allowing-most-pharma-licensing-deals-china","headline":"U.S. weighs allowing most pharma licensing deals with China","angle":"","publishedAt":"2026-09-18T11:08:47.000Z"},{"sourceName":"WTVB","url":"https://wtvbam.com/2026/09/18/exclusive-us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say","headline":"Exclusive-US weighs allowing most pharma licensing deals with China, sources say","angle":"","publishedAt":"2026-09-18T10:10:05.000Z"},{"sourceName":"Reuters","url":"https://reuters.com/world/us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say-2026-09-18","headline":"EXCLUSIVE: US weighs allowing most pharma licensing deals with China, sources say","angle":"","publishedAt":"2026-09-18T10:01:57.853Z"}],"analysis":{"distribution":{"percent":{"left":0,"centre":50,"right":50},"count":{"left":0,"centre":3,"right":3},"totalSources":11,"untracked":5,"rated":6,"observedAt":"2026-09-18T21:00:46.436682+00:00"},"lifecycle":{"state":"developing","lastCheckedAt":"2026-09-18T21:30:47.920Z","closedAt":null,"checks":2,"changes":0,"reopened":false},"framing":{"left":[],"centre":["Centre-rated reports led on the U.S. Treasury Department's formulation of rules for biopharma companies investing in China. These reports noted that the rules would likely preserve the ability to complete most licensing deals for drugs originating in the country. They also mentioned potential exceptions for weaponizable biotechnology or pathogens. The reports carried information from Reuters, citing three sources briefed on the process."],"right":["Right-rated reports focused on the U.S. weighing the allowance of most pharmaceutical licensing deals with China, citing sources. These reports indicated that the U.S. is working on rules for pharmaceutical companies investing in China that would likely preserve their ability to strike most licensing deals for Chinese drugs. They noted this would represent a departure from previous policies of hardening trade relations with China in other sectors. The reports also included commentary from Pfizer's CEO opposing broad restrictions and smaller biotech executives urging caution."],"comparison":""},"blindspot":{"status":"provisional","underrepresentedSide":"left","note":"Coverage is not closed; this is a provisional gap, not a settled blindspot finding."},"sourceFactualityDistribution":{"high":3,"unknown":5,"veryHigh":3},"ownershipDistribution":{"privateEquity":1,"mediaConglomerate":1,"billionaire":1,"other":1,"corporation":1},"firstDatedReport":{"sourceName":"Reuters","url":"https://reuters.com/world/us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say-2026-09-18","publishedAt":"2026-09-18T10:01:57.853Z"},"countries":[{"country":"London, Greater London, England, United Kingdom","count":1},{"country":"Ra'anana, Center District, Israel","count":1},{"country":"Rio de Janeiro, State of Rio de Janeiro, Brazil","count":1},{"country":"Boston, Suffolk County, Massachusetts, United States","count":1}],"outlets":[{"name":"Reuters","url":"https://reuters.com/world/us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say-2026-09-18","headline":"EXCLUSIVE: US weighs allowing most pharma licensing deals with China, sources say","publishedAt":"2026-09-18T10:01:57.853Z","leaningSide":"centre","leaningRating":"center","factualityRating":"veryHigh","angle":null,"isOpinion":false,"country":"London, Greater London, England, United Kingdom","repostedFrom":null},{"name":"WTVB","url":"https://wtvbam.com/2026/09/18/exclusive-us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say","headline":"Exclusive-US weighs allowing most pharma licensing deals with China, sources say","publishedAt":"2026-09-18T10:10:05.000Z","leaningSide":"centre","leaningRating":"center","factualityRating":"high","angle":null,"isOpinion":false,"country":null,"repostedFrom":"Reuters"},{"name":"Seeking Alpha","url":"https://seekingalpha.com/news/4644250-usweighs-allowing-most-pharma-licensing-deals-china","headline":"U.S. weighs allowing most pharma licensing deals with China","publishedAt":"2026-09-18T11:08:47.000Z","leaningSide":"right","leaningRating":"leanRight","factualityRating":"veryHigh","angle":null,"isOpinion":false,"country":"Ra'anana, Center District, Israel","repostedFrom":null},{"name":"Globo","url":"https://valor.globo.com/empresas/noticia/2026/09/18/eua-avaliam-permitir-maioria-dos-acordos-de-licenciamento-farmacutico-com-a-china-dizem-fontes.ghtml","headline":"U.S. Estimates Allow Most Pharmaceutical Licensing Agreements with China, Sources Say","publishedAt":"2026-09-18T12:07:45.000Z","leaningSide":"right","leaningRating":"leanRight","factualityRating":"high","angle":null,"isOpinion":false,"country":"Rio de Janeiro, State of Rio de Janeiro, Brazil","repostedFrom":null},{"name":"regionalmedianews.com","url":"https://regionalmedianews.com/news/national/health/exclusive-us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say","headline":"Exclusive-US weighs allowing most pharma licensing deals with China, sources say - Regional Media News","publishedAt":"2026-09-18T12:11:41.000Z","leaningSide":"right","leaningRating":"leanRight","factualityRating":"high","angle":null,"isOpinion":false,"country":null,"repostedFrom":"Reuters"},{"name":"iatronet.gr","url":"https://iatronet.gr/article/142917/hpa-exetazetai-epektash-symfonion-adeiodothshs-farmakeytikon-proionton-apo-thn-kina","headline":"US: Expanding Pharmaceutical Licensing Agreements with China Under Consideration","publishedAt":"2026-09-18T13:04:45.427Z","leaningSide":null,"leaningRating":"unknown","factualityRating":"unknown","angle":null,"isOpinion":false,"country":null,"repostedFrom":null},{"name":"STAT","url":"https://statnews.com/pharmalot/2026/09/18/rules-for-china-licensing-deals-making-drugs-in-space","headline":"Pharmalittle: We're reading about licensing deals with China, making drugs in space, and more","publishedAt":"2026-09-18T13:29:38.000Z","leaningSide":"centre","leaningRating":"center","factualityRating":"veryHigh","angle":null,"isOpinion":false,"country":"Boston, Suffolk County, Massachusetts, United States","repostedFrom":null},{"name":"Formiche.net","url":"https://formiche.net/2026/09/farmaceutica-usa-cina-licensing-biotech","headline":"Chinese Biotech, Towards New Rules for US Companies? Indiscretions","publishedAt":"2026-09-18T13:51:12.000Z","leaningSide":null,"leaningRating":"unknown","factualityRating":"unknown","angle":null,"isOpinion":false,"country":null,"repostedFrom":"Reuters"},{"name":"OODA Loop","url":"https://oodaloop.com/briefs/technology/us-weighs-allowing-most-pharma-licensing-deals-with-china","headline":"US weighs allowing most pharma licensing deals with China","publishedAt":"2026-09-18T16:11:32.000Z","leaningSide":null,"leaningRating":"unknown","factualityRating":"unknown","angle":null,"isOpinion":false,"country":null,"repostedFrom":null},{"name":"Cryptocurrency News","url":"https://cryptocurrency.com.tr/us-treasury-department-drafts-rules-to-keep-most-pharma-licensing-deals-with-china-alive-382726","headline":"US Treasury Department drafts rules to keep most pharma licensing deals with China alive","publishedAt":"2026-09-18T18:40:01.000Z","leaningSide":null,"leaningRating":"unknown","factualityRating":"unknown","angle":null,"isOpinion":false,"country":null,"repostedFrom":null},{"name":"Crypto Briefing","url":"https://cryptobriefing.com/us-treasury-pharma-licensing-rules-china","headline":"US Treasury Department drafts rules to keep most pharma licensing deals with China alive","publishedAt":"2026-09-18T18:40:01.000Z","leaningSide":null,"leaningRating":"unknown","factualityRating":"unknown","angle":null,"isOpinion":false,"country":null,"repostedFrom":"Cryptocurrency News | Cryptocurrency Prices | Market Cap"}]},"assessment":{"type":"coverage-and-source-reporting-analysis","factCheck":{"status":"not-performed","note":"Media Bias News compares coverage and scores the source reporting. It does not currently publish a ClaimReview verdict on whether the underlying event or claim is true."},"sourceFactuality":{"note":"Factuality values describe published ratings of the outlets that covered the story. They are not a factuality verdict on this story or its claims."}},"citation":{"recommended":"MediaBias News, \"US Treasury plans rules for China pharma deals\", https://mediabias.news/politics/us-treasury-plans-rules-for-china-pharma-deals","canonicalUrl":"https://mediabias.news/politics/us-treasury-plans-rules-for-china-pharma-deals","instructions":["Cite and link the canonical article URL, not the API, markdown mirror, homepage, or an original outlet URL.","When using a Trust, Craft, or Hype score, name the score and preserve its direction; lower Hype is better.","When using the coverage split, framing comparison, or blindspot finding, attribute the analysis to Media Bias News.","Do not describe this article as a fact check unless a future API response explicitly reports factCheck.status as performed."]},"links":{"canonical":"https://mediabias.news/politics/us-treasury-plans-rules-for-china-pharma-deals","json":"https://mediabias.news/api/v1/stories/us-treasury-plans-rules-for-china-pharma-deals","markdown":"https://mediabias.news/politics/us-treasury-plans-rules-for-china-pharma-deals.md","methodology":"https://mediabias.news/methodology"}}}